Medscape www.medscape.com

References for:
Is the Male Genital Tract Really a Sanctuary Site for HIV? Arguments That it is not.

[AIDS 18(10):1353-1362, 2004. © 2004 Lippincott Williams & Wilkins]

  1. Hoetelmans RM. Sanctuary sites in HIV-1 infection. Antivir Ther 1998; 3 (Suppl. 4):13-17.
  2. Kashuba ADM, Dyer JR, Kramer LM, Raasch RH, Eron JJ, Cohen MS. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999; 43:1817-1826.
  3. Taylor S, Pereira AS. Antiretroviral drug concentrations in semen of HIV-1 infected men. Sex Transm Infect 2001; 77: 4-11.
  4. Pomerantz RJ. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. Clin Infect Dis 2002; 34:91-97.
  5. Taylor S, Boffito M, Vernazza PL. Antiretroviral therapy to reduce the sexual transmission of HIV. J HIV Ther 2003; 8: 55-66.
  6. Saksena NK, Potter SJ. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy. AIDS Rev 2003; 5:3-18.
  7. Reddy YS, Kashuba A, Gerber J, Miller V. Roundtable report: importance of antiretroviral drug concentrations in sanctuary sites and viral reservoirs. AIDS Res Hum Retroviruses 2003; 19:167-176.
  8. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002; 53: 557-593.
  9. Gisslen M, Hagberg L. Antiretroviral treatment of central nervous system HIV-1 infection: a review. HIV Med 2001; 2:97-104.
  10. Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslen M. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS 2002; 16:2145-2149.
  11. Tashima KT, Flanigan TP, Kurpewski J, Melanson SM, Skolnik PR. Discordant human immunodeficiency virus type 1 drug resistance mutations, including K103N, observed in cerebrospinal fluid and plasma. Clin Infect Dis 2002; 35:82-83.
  12. Coombs RW, Reichelderfer PS, Landay AL. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS 2003; 17:455-480.
  13. Dejucq N, Jegou B. Viruses in the mammalian male genital tract and their effects on the reproductive system. Microbiol Mol Biol Rev 2001; 65:208-231.
  14. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
  15. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-188.
  16. Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002; 16:1511-1519.
  17. Ristig MB, Arens MQ, Kennedy M, Powderly W, Tebas P. Increasing prevalence of resistance mutations in antiretroviral-naive individuals with established HIV-1 infection from 1996-2001 in St Louis. HIV Clin Trials 2002; 3:155-160.
  18. Taylor S, Cane P, Hue S, Xu L, Wrin T, Lie Y, et al. Identification of a transmission chain of HIV Type 1 containing drug resistance-associated mutations. AIDS Res Hum Retroviruses 2003; 19:353-361.
  19. Wensing AMJ, Van de Vijver DAMC, Asjo B, Balotta C, Camacho R, De Luca A, et al. Analysis from more than 1600 newly diagnosed patients with HIV from 17 European countries shows that 10% of the patients carry primary drug resistance: the CATCH Study. In: 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13-16 July 2003 [Abstract LB01].
  20. Wensing A, Van de Vijver D, Angarano G, Asjo B, Balotta C, Boeri E, et al. Drug susceptibility patterns in 195 European patients de novo infected with drug resistant virus: implications for post-exposure prophylaxis. In: 9th European AIDS Conference (EACS). Warsaw, Poland, 25-29 October 2003 [Abstract LBF6/1].
  21. Wensing AM, Boucher CA. Worldwide transmission of drug-resistant HIV. AIDS Rev 2003; 5:140-155.
  22. Tortora GJ, Grabowski SR, editors. The reproductive systems. In: Principles of anatomy and physiology. New York: John Wiley and Sons, Inc.; 2000. pp. 974-1021.
  23. Junqueira LC, Carneiro J, Kelley RO, editors. Het mannelijk genitaalstelsel. In: Functionele histologie. Maarssen: Elsevier; 2000. pp. 515-533.
  24. Marieb E, editor. The reproductive system. In: Human anatomy and physiology. New York: Addison Wesley Longman, Inc.; 1997. pp. 1030-1077.
  25. Stevens A, Lowe JS, editors. Male reproductive system. In: Human histology. London: Mosby; 1997. pp. 309-326.
  26. Ganong WF, editor. The gonads: development and function of the reproductive system. In: Review of medical physiology. Toronto: Prentice Hall International Inc.; 1995. pp. 379-417.
  27. World Health Organization (WHO). WHO laboratory manual for the examination of human semen and semen-cervical mucus interaction. 3. Cambridge, UK: Cambridge University Press; 1992.
  28. Polakoski KL, Syner FN, Zaneveld LJD. Biochemistry of human seminal plasma. In: Human semen and fertility regulation in men. Hafez ESE, editor. Saint Louis: The CV Mosby Company; 1976. pp. 133-143.
  29. Krieger JN, Nirapathpongporn A, Chaiyaporn M, Peterson G, Nikolaeva I, Akridge R, et al. Vasectomy and human immunodeficiency virus type 1 in semen. J Urol 1998; 159:820-825.
  30. el Demiry MI, Hargreave TB, Busuttil A, James K, Ritchie AW, Chisholm GD. Lymphocyte sub-populations in the male genital tract. Br J Urol 1985; 57:769-774.
  31. Ritchie AW, Hargreave TB, James K, Chisholm GD. Intra-epithelial lymphocytes in the normal epididymis. A mechanism for tolerance to sperm auto-antigens? Br J Urol 1984; 56: 79-83.
  32. Simbini T, Umapathy E, Jacobus E, Tendaupenyu G, Mbizvo MT. Study on the origin of seminal leucocytes using split ejaculate technique and the effect of leucocytospermia on sperm characteristics. Urol Int 1998; 61:95-100.
  33. Anderson DJ, Politch JA, Martinez A, Van Voorhis BJ, Padian NS, O'Brien TR. White blood cells and HIV-1 in semen from vasectomised seropositive men. Lancet 1991; 338:573-574.
  34. Olsen GP, Shields JW. Seminal lymphocytes, plasma and AIDS. Nature 1984; 309:116-117.
  35. Kashuba ADM, Dyer JR, Kramer LM, Raasch RH, Eron JJ, Cohen MS. Author's correction. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44:1119-1119.
  36. Gallicano K. Antiretroviral-drug concentrations in semen. Antimicrob Agents Chemother 2000; 44:1117-1118.
  37. Hoggard PG, Back DJ. Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules. Curr Opin Infect Dis 2002; 15:3-8.
  38. van Praag RME, Weverling GJ, Portegies P, Jurriaans S, Zhou XJ, Turner-Foisy ML, et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 2000; 14:1187-1194.
  39. Sankatsing SUC, Beijnen JH, Schinkel AH, Lange JMA, Prins JM. P-glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother 2004; 48: 43-52.
  40. Van Praag RM, Repping S, de Vries JW, Lange JM, Hoetelmans RM, Prins JM. Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma. Antimicrob Agents Chemother 2001; 45:2902-2907.
  41. Back D, Blaschke T, Boucher C, Burger D, Fletcher C, Flexner C, et al. Therapeutic drug monitoring guidelines. Therapeutic ranges for antiretroviral drugs. Available at: www.HIVpharmacology.com. 2003. Accessed March 2004.
  42. Kumar PN, Sweet DE, McDowell JA, Symonds W, Lou Y, Hetherington S, LaFon S. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 1999; 43:603-608.
  43. Van Praag RM, van Heeswijk RP, Jurriaans S, Lange JM, Hoetelmans RM, Prins JM. Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1. Clin Infect Dis 2001; 33: e91-e92.
  44. Liverpool HIV Pharmacology Group. Drug pharmacokinetic profiles. Available at: www.HIVpharmacology.com 2003. Accessed March 2004.
  45. Gatti G, Bonora S, Liuzzi G, Guaraldi G, Bucci B, De Pascalis CR, et al. DDI concentrations in seminal plasma. In: 8th European Conference on Clinical Aspects and Treatment of HIV Infection (ECCATH). Athens, Greece, 28-31 October 2001 [Abstract P 157].
  46. Bruno R, Regazzi MB, Ciappina V, Villani P, Sacchi P, Montagna M, et al. Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV. Clin Pharmacokinet 2001; 40:695-700.
  47. Pereira AS, Smeaton LM, Gerber JG, Acosta EP, Snyder S, Fiscus SA, et al. The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850). J Infect Dis 2002; 186:198-204.
  48. Pereira AS, Kashuba ADM, Fiscus AA, Hall JE, Tidwell RR, Troiani L, et al. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J Infect Dis 1999; 180:2039-2043.
  49. Reijers M, van Heeswijk R, Schuitemaker H, Portegies P, Weverling GJ, Lange J, Hoetelmans R. The concentrations of d4T, 3TC, nelfinavir (NFV) and saquinavir (SQV) in plasma, cerebrospinal fluid (CSF), and semen. In: 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, 30 January-2 February 2000 [Abstract 316].
  50. Taylor S, van Heeswijk RPG, Hoetelmans RMW, Workman J, Drake SM, White DJ, Pillay D. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1 infected men. AIDS 2000; 14:1979-1984.
  51. Taylor S, Reynolds H, Sabin CA, Drake SM, White DJ, Back DJ, Pillay D. Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. AIDS 2001; 15:2051-2053.
  52. Reddy YS, Gotzkowsky SK, Eron JJ, Kim JY, Fiske WD, Fiscus SA, et al. Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. J Infect Dis 2002; 186:1339-1343.
  53. van Heeswijk RPG, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FWNM, Lange JMA, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1 infected individuals. AIDS 2000; 14:F77-F82.
  54. Hayashi S, Jayesekera D, Jayewardene A, Shah A, Thevanayagam L, Aweeka F. Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients. J Clin Pharmacol 1999; 39:1085-1093.
  55. Taylor S, Back DJ, Drake SM, Workman J, Reynolds H, Gibbons SE, et al. Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. J Antimicrob Chemother 2001; 48:351-354.
  56. Lafeuillade A, Solas C, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials 2002; 3:27-35.
  57. Lafeuillade A, Solas C, Chadapaud S, Hittinger G, Poggi C, Lacarelle B. HIV-1 RNA levels, resistance, and drug diffusion in semen versus blood in patients receiving a lopinavir-containing regimen. J Acquired Immune Defic Syndr 2003; 32:462-464.
  58. Sankatsing SU, Droste J, Burger D, Van Praag RM, Jurriaans S, Lange JM, Prins JM. Limited penetration of lopinavir into seminal plasma of HIV-1-infected men. AIDS 2002; 16: 1698-1700.
  59. Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs 2000; 59:581-620.
  60. Regazzi MB, Villani P, Maserati R, Cocchi L, Giacchino R, Burroni D, Rettani M. Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV-1 infected individuals. Br J Clin Pharmacol 1999; 47:379-382.
  61. Fawcett DW, Leak LV, Heidger PM Jr. Electron microscopic observations on the structural components of the blood-testis barrier. J Reprod Fertil Suppl 1970; 10:105-122.
  62. Holash JA, Harik SI, Perry G, Stewart PA. Barrier properties of testis microvessels. Proc Natl Acad Sci U S A 1993; 90: 11069-11073.
  63. Bart J, Groen HJ, van der Graaf WT, Hollema H, Hendrikse NM, Vaalburg W, et al. An oncological view on the blood-testis barrier. Lancet Oncol 2002; 3:357-363.
  64. Setchell BP. The movement of fluids and substances in the testis. Aust J Biol Sci 1986; 39:193-207.
  65. Renkin EM, Crone C. Microcirculation and capillary exchange. In: Comprehensive human physiology. Greger R, Windhorst U, editors. Berlin: Springer-Verlag; 1996. pp. 1965-1979.
  66. Bernards JA, Bouman LN, editors. Bloedsomloop. In: Fysiology van de mens. Houten: Bohn Stafleu Van Loghem; 1994. pp. 269-346.
  67. Russell LD. The blood-testis barrier and its formation relative to spermatocyte maturation in the adult rat: a lanthanum tracer study. Anat Rec 1978; 190:99-111.
  68. Mancini RE, Vilar O, Alvarez B, Seiguer AC. Extravascular and intratubular diffusion of labeled serum proteins in the rat testis. J Histochem Cytochem 1965; 13:376-385.
  69. Tortora GJ, Grabowski SR, editors. The cardiovascular system: blood vessels and hemodynamics. In: Principles of anatomy and physiology. New York: John Wiley and Sons, Inc.; 2000. pp. 670-737.
  70. Gartner LP, Hiatt JL, editors. Circulatory system. In: Color textbook of histology. Philadelphia: WB Saunders Company; 2001. pp. 251-271.
  71. Berne RM, Levy MN, editors. The microcirculation and lymphatics. In: Physiology. St Louis: Mosby, Inc.; 1998. pp. 429-441.
  72. Junqueira LC, Carneiro J, Kelley RO, editors. Het circulatiesysteem. In: Functionele histolgie. Maarssen: Elsevier; 2000. pp. 265-282.
  73. Marchlewicz M. Localization of immunocompetent cells in the human epididymis. Folia Histochem Cytobiol 2001; 39: 173-174.
  74. Marchlewicz M, Wenda-Rozewicka L, Wiszniewska B, Piasecka M, Swider-al-Amawi M. Permeability of blood-testis and blood-epididymis barriers to Hoechst 33342 dye. Folia Histochem Cytobiol 1999; 37:85-86.
  75. Alexander NJ. HIV and germinal cells: how close an association? J Reprod Immunol 1998; 41:17-26.
  76. Baccetti B, Benedetto A, Collodel G, di Caro A, Garbuglia AR, Piomboni P. The debate on the presence of HIV-1 in human gametes. J Reprod Immunol 1998; 41:41-67.
  77. Shevchuk MM, Nuovo GJ, Khalife G. HIV in testis: quantitative histology and HIV localization in germ cells. J Reprod Immunol 1998; 41:69-79.
  78. Piomboni P, Baccetti B. Spermatozoon as a vehicle for HIV-1 and other viruses: a review. Mol Reprod Dev 2000; 56: 238-242.
  79. Werner A, Winskowsky G, Cichutek K, Norley SG, Kurth R. Productive infection of both CD4+ and CD4- human cell lines with HIV-1, HIV-2 and SIVagm. AIDS 1990; 4:537-544.
  80. Bourinbaiar AS, Phillips DM. Transmission of human immunodeficiency virus from monocytes to epithelia. J Acquired Immune Defic Syndr 1991; 4:56-63.
  81. Phillips DM, Bourinbaiar AS. Mechanism of HIV spread from lymphocytes to epithelia. Virology 1992; 186:261-273.
  82. Pearce-Pratt R, Phillips DM. Studies of adhesion of lymphocytic cells: implications for sexual transmission of human immunodeficiency virus. Biol Reprod 1993; 48:431-445.
  83. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med 1997; 3:42-47.
  84. Meng G, Wei X, Wu X, Sellers MT, Decker JM, Moldoveanu Z, et al. Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat Med 2002; 8:150-156.
  85. Gil T, Castilla JA, Hortas ML, Molina J, Redondo M, Samaniego F, et al. CD4+ cells in human ejaculates. Hum Reprod 1995; 10:2923-2927.
  86. Pudney J, Anderson D. Orchitis and human immunodeficiency virus type 1 infected cells in reproductive tissues from men with the acquired immune deficiency syndrome. Am J Pathol 1991; 139:149-160.
  87. Mermin JH, Holodniy M, Katzenstein DA, Merigan TC. Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. J Infect Dis 1991; 164:769-772.
  88. Quayle AJ, Xu C, Mayer KH, Anderson DJ. T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. J Infect Dis 1997; 176:960-968.
  89. Dalton AD, Harcourt-Webster JN. The histopathology of the testis and epididymis in AIDS - a post-mortem study. J Pathol 1991; 163:47-52.
  90. Shevchuk MM, Pigato JB, Khalife G, Armenakas NA, Fracchia JA. Changing testicular histology in AIDS: its implication for sexual transmission of HIV. Urology 1999; 53:203-208.
  91. Pasquier C, Bujan L, Daudin M, Righi L, Berges L, Thauvin L, et al. Intermittent detection of hepatitis C virus (HCV) in semen from men with human immunodeficiency virus type 1 (HIV-1) and HCV. J Med Virol 2003; 69:344-349.
  92. Liuzzi G, D'Offizi G, Topino S, Zaccarelli M, Amendola A, Capobianchi MR, et al. Dynamics of viral load rebound in plasma and semen after stopping effective antiretroviral therapy. AIDS 2003; 17:1089-1092.
  93. Bujan L, Daudin M, Alvarez M, Massip P, Puel J, Pasquier C. Intermittent human immunodeficiency type 1 virus (HIV-1) shedding in semen and efficiency of sperm processing despite high seminal HIV-1 RNA levels. Fertil Steril 2002; 78: 1321-1323.
  94. Kulkosky J, Nunnari G, Otero M, Calarota S, Dornadula G, Zhang H, et al. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J Infect Dis 2002; 186:1403-1411.
  95. Choudhury B, Pillay D, Taylor S, Cane PA. Analysis of HIV-1 variation in blood and semen during treatment and treatment interruption. J Med Virol 2002; 68:467-472.
  96. Leruez-Ville M, Dulioust E, Costabliola D, Salmon D, Tachet A, Finkielsztejn L, et al. Decrease in HIV-1 seminal shedding in men receiving highly active antiretroviral therapy: an 18 month longitudinal study (ANRS EP012). AIDS 2002; 16:486-488.
  97. Taylor S, Ferguson NM, Cane PA, Anderson RM, Pillay D. Dynamics of seminal plasma HIV-1 decline after antiretroviral treatment. AIDS 2001; 15:424-426.
  98. Barroso PF, Schechter M, Gupta P, Melo MF, Vieira M, Murta FC, et al. Effect of antiretroviral therapy on HIV shedding in semen. Ann Intern Med 2000; 133:280-284.
  99. Barroso PF, Schechter M, Gupta P, Bressan C, Bomfim A, Harrison LH. Adherence to antiretroviral therapy and persistence of HIV RNA in semen. J Acquired Immune Defic Syndr 2003; 32:435-440.
  100. Eron JJ, Smeaton LM, Fiscus SA, Gulick RM, Currier JS, Lennox JL, et al. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850). J Infect Dis 2000; 181: 1622-1628.
  101. Liuzzi G, Chirianni A, Bagnarelli P, Clementi M, Piazza M. A combination of nucleoside analogues and a protease inhibitor reduces HIV-1 RNA levels in semen: implications for sexual transmission of HIV infection. Antivir Ther 1999; 4:95-99.
  102. Mayer KH, Boswell S, Goldstein R, Lo W, Xu C, Tucker L, et al. Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Clin Infect Dis 1999; 28:1252-1259.
  103. Fiscus SA, Vernazza PL, Gilliam B, Dyer J, Eron JJ, Cohen MS. Factors associated with changes in HIV shedding in semen. AIDS Res Hum Retroviruses 1998; 14 (Suppl. 1):S27-S31.
  104. Merigan TC. Use of PCR to measure HIV viral changes in drug-resistant genes in genital fluids. J Reprod Immunol 1998; 41:177-185.
  105. Vernazza PL, Gilliam BL, Flepp M, Dyer JR, Frank AC, Fiscus SA, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 1997; 11:1249-1254.
  106. Gilliam BL, Dyer JR, Fiscus SA, Marcus C, Zhou S, Wathen L, et al. Effects of reverse transcriptase inhibitor therapy on the HIV-1 viral burden in semen. J Acquired Immune Defic Syndr Hum Retrovirol 1997; 15:54-60.
  107. Dyer JR, Gilliam BL, Eron JJ Jr, Cohen MS, Fiscus SA, Vernazza PL. Shedding of HIV-1 in semen during primary infection. AIDS 1997; 11:543-545.
  108. Gupta P, Mellors J, Kingsley L, Riddler, S, Singh MK, Schreiber S, et al. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol 1997; 71:6271-6275.
  109. Hamed KA, Winters MA, Holodniy M, Katzenstein DA, Merigan TC. Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy. J Infect Dis 1993; 167:798-802.
  110. Chakraborty H, Helms RW, Sen PK, Cohen MS. Estimating correlation by using a general linear mixed model: evaluation of the relationship between the concentration of HIV-1 RNA in blood and semen. Stat Med 2003; 22:1457-1464.
  111. Ball JK, Rowe T, Curran R, Irving WL, Beards GM, Sontag G, et al. Poor reduction of HIV-1 RNA titres in nucleoside reverse transcriptase inhibitor experienced patients treated with indinavir combination therapy. Sex Transm Infect 1999; 75: 337-339.
  112. Pilcher CD, Shugars DC, Fiscus SA, Miller WC, Menezes P, Giner J, et al. HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS 2001; 15:837-845.
  113. Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47:238-243.
  114. Sadiq ST, Taylor S, Kaye S, Bennett J, Johnstone R, Byrne P, et al. The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis. AIDS 2002; 16:219-225.
  115. Nunnari G, Otero M, Dornadula G, Vanella M, Zhang H, Frank I, Pomerantz RJ. Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections. AIDS 2002; 16:39-45.
  116. Celum CL, Buchbinder SP, Donnell D, Douglas JM Jr, Mayer K, Koblin B, et al. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis 2001; 183: 23-35.
  117. Gunthard HF, Havlir DV, Fiscus S, Zhang ZQ, Eron J, Mellors J, et al. Residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis 2001; 183:1318-1327.
  118. Vernazza PL, Troiani L, Flepp MJ, Cone RW, Schock J, Roth F, et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding. AIDS 2000; 14:117-121.
  119. Shepard RN, Schock J, Robertson K, Shugars DC, Dyer J, Vernazza P, et al. Quantitation of human immunodeficiency virus type 1 RNA in different biological compartments. J Clin Microbiol 2000; 38:1414-1418.
  120. Eyre RC, Zheng G, Kiessling AA. Multiple drug resistance mutations in human immunodeficiency virus in semen but not in blood of a man on antiretroviral therapy. Urology 2000; 55:591XVII-591XX.
  121. Ball JK, Curran R, Irving WL, Dearden AA. HIV-1 in semen: determination of proviral and viral titres compared to blood, and quantification of semen leukocyte populations. J Med Virol 1999; 59:356-363.
  122. Tachet A, Dulioust E, Salmon D, De Almeida M, Rivalland D, Finkielsztejn L, et al. Detection and quantification of HIV-1 in semen: identification of a subpopulation of men at high potential risk of viral sexual transmission. AIDS 1999; 13: 823-831.
  123. Speck CE, Coombs RW, Koutsky LA, Zeh J, Ross SO, Hooton TM, et al. Risk factors for HIV-1 shedding in semen. Am J Epidemiol 1999; 150:622-631.
  124. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999; 282:1627-1632.
  125. Zhang H, Dornadula G, Beumont M, Livornese L, Van Uitert B, Henning K, Pomerantz RJ. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretoviral therapy. N Engl J Med 1998; 339:1803-1809.
  126. Dyer JR, Kazembe P, Vernazza PL, Gilliam BL, Maida M, Zimba D, et al. High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis 1998; 177:1742-1746.
  127. Vernazza PL, Gilliam BL, Dyer J, Fiscus SA, Eron JJ, Frank AC, et al. Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS 1997; 11:987-993.
  128. Byrn RA, Zhang D, Eyre R, McGowan K, Kiessling AA. HIV-1 in semen: an isolated virus reservoir. Lancet 1997; 350:1141.
  129. Bourlet T, Cazorla C, Berthelot P, Grattard F, Cognasse F, Fresard A, et al. Compartmentalization of HIV-1 according to antiretroviral therapy: viral loads are correlated in blood and semen but poorly in blood and saliva. AIDS 2001; 15:284-285.
  130. Winter AJ, Taylor S, Workman J, White D, Ross JD, Swan AV, Pillay D. Asymptomatic urethritis and detection of HIV-1 RNA in seminal plasma. Sex Transm Infect 1999; 75:261-263.
  131. Taylor S, Sadiq T, Sabin C, White D, Cane P, Drake S, Pillay D. Seminal super shedding of HIV: implications for sexual transmission. In: 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, USA, 10-14 February 2003 [Abstract 454].
  132. Sankatsing SU, Van Praag RM, van Rij RP, Rientsma R, Jurriaans S, Lange JM, et al. Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection. Antivir Ther 2003; 8:137-142.
  133. van Rij RP, Van Praag RM, Prins JM, Rientsma R, Jurriaans S, Lange JM, Schuitemaker H. Persistence of viral HLA-DR- CD4 T-cell reservoir during prolonged treatment of HIV-1 infection with a five-drug regimen. Antivir Ther 2002; 7:37-41.
  134. Blankson JN, Finzi D, Pierson TC, Sabundayo BP, Chadwick K, Margolick JB, et al. Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182:1636-1642.
  135. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000; 6:82-85.
  136. Viard J, Burgard M, Hubert J, Aaron L, Rabian C, Pertuiset N, et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 2004; 18:45-49.
  137. Bushman F. Measuring covert HIV replication during HAART: the abundance of 2-LTR circles is not a reliable marker. AIDS 2003; 17:749-750.
  138. Brussel A, Mathez D, Broche-Pierre S, Lancar R, Calvez T, Sonigo P, Leibowitch J. Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection. AIDS 2003; 17:645-652.
  139. Morlese J, Teo IA, Choi JW, Gazzard B, Shaunak S. Identification of two mutually exclusive groups after long-term monitoring of HIV DNA 2-LTR circle copy number in patients on HAART. AIDS 2003; 17:679-683.
  140. Eron JJ, Vernazza PL, Johnston DM, Seillier-Moiseiwitsch F, Alcorn TM, Fiscus SA, Cohen MS. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS 1998; 12:F181-F189.
  141. Kroodsma KL, Kozal MJ, Hamed KA, Winters MA, Merigan TC. Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. J Infect Dis 1994; 170:1292-1295.
  142. Taylor S, Tariq Sadiq S, Weller I, Kaye S, Workman J, Cane PA, et al. Drug-resistant HIV-1 in the semen of men receiving antiretroviral therapy with acute sexually transmitted infections. Antivir Ther 2003; 8:479-483.
  143. Delassus S, Cheynier R, Wain-Hobson S. Nonhomogeneous distribution of human immunodeficiency virus type 1 proviruses in the spleen. J Virol 1992; 66:5642-5645.
  144. Ball JK, Holmes EC, Whitwell H, Desselberger U. Genomic variation of human immunodeficiency virus type 1 (HIV-1): molecular analyses of HIV-1 in sequential blood samples and various organs obtained at autopsy. J Gen Virol 1994; 75: 867-879.
  145. Liuzzi G, Chirianni A, Clementini M, Bagnarelli P, Valenza A, Cataldo PT, Piazza M.. Analysis of HIV-1 load in blood, semen, and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS 1996; 10:F51-F56.
  146. Coombs RW, Speck CE, Hughes JP, Lee W, Sampoleo R, Ross SO, et al. Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis 1998; 177: 320-330.
  147. Kiessling AA, Fitzgerald LM, Zhang D, Chhay H, Brettler D, Eyre RC, et al. Human immunodeficiency virus in semen arises from a genetically distinct virus reservoir. AIDS Res Hum Retroviruses 1998; 14 (Suppl. 1):S33-S41.
  148. Gupta P, Leroux C, Patterson BK, Kingsley L, Rinalco C, Ding M, et al. Human immunodeficiency virus type 1 shedding pattern in semen correlates with the compartmentalization of viral quasi species between blood and semen. J Infect Dis 2000; 182:79-87.
  149. Curran R, Ball JK. Concordance between semen-derived HIV-1 proviral DNA and viral RNA hypervariable region 3 (V3) envelope sequences in cases where semen populations are distinct from those present in blood. J Med Virol 2002; 67: 9-19.
  150. Paranjpe S, Craigo J, Patterson B, Ding M, Barroso P, Harrison L, et al. Subcompartmentalization of HIV-1 quasispecies between seminal cells and seminal plasma indicates their origin in distinct genital tissues. AIDS Res Hum Retroviruses 2002; 18:1271-1280.
  151. Herak-Kramberger CM, Breton S, Brown D, Kraus O, Sabolic I. Distribution of the vacuolar H+ atpase along the rat and human male reproductive tract. Biol Reprod 2001; 64: 1699-1707.
  152. Levine N, Kelly H. Measurement of pH in the rat epididymis in vivo. J Reprod Fertil 1978; 52:333-335.
  153. Levine N, Marsh DJ. Micropuncture studies of the electrochemical aspects of fluid and electrolyte transport in individual seminiferous tubules, the epididymis and the vas deferens in rats. J Physiol 1971; 213:557-570.
  154. Rodriguez-Martinez H, Ekstedt E, Einarsson S. Acidification of epididymal fluid in the boar. Int J Androl 1990; 13:238-243.
  155. Mann T, Lutwak-Mann C, editors. Epididymis and epididymal semen. In: Male reproductive function and semen. Berlin: Springer-Verlag; 1981. pp. 139-159.
  156. Blacklock NJ, Beavis JP. The response of prostatic fluid pH in inflammation. Br J Urol 1974; 46:537-542.
  157. Pfau A, Perlberg S, Shapira A. The pH of the prostatic fluid in health and disease: implications of treatment in chronic bacterial prostatitis. J Urol 1978; 119:384-387.
  158. Huaijin C, Junyan Z, Naiguan C. Prostatic fluid and sperm examination: 106 cases. Preliminary study on infertility. Acta Urol Belg 1998; 66:19-21.
  159. Fair WR, Cordonnier JJ. The pH of prostatic fluid: a reappraisal and therapeutic implications. J Urol 1978; 120:695-698.
  160. Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol 2001; 69:522-530.
  161. Beagley KW, Wu ZL, Pomering M, Jones RC. Immune responses in the epididymis: implications for immunocontraception. J Reprod Fertil Suppl 1998; 53:235-245.
  162. Robertson SA, Ingman WV, O'Leary S, Sharkey DJ, Tremellen KP. Transforming growth factor beta - a mediator of immune deviation in seminal plasma. J Reprod Immunol 2002; 57: 109-128.
  163. Kelly RW. Immunosuppressive mechanisms in semen: implications for contraception. Hum Reprod 1995; 10:1686-1693.
  164. Witkin SS. Mechanisms of active suppression of the immune response to spermatozoa. Am J Reprod Immunol Microbiol 1988; 17:61-64.
  165. Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986; 234:1563-1566.
  166. Levy JA, Mackewicz CE, Barker E. Controlling HIV-1 pathogenesis: the role of the non-cytotoxic anti HIV-1 response of CD8+ T cells. Immunol Today 1996; 17:217-224.
  167. Zhang L, Yu W, He T, Yu J, Caffrey RE, Dalmasso EA, et al. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 2002; 298: 995-1000.
  168. Zagury D, Bernard J, Leibowitch J, Safai B, Groopman JE, Feldman M, et al. HTLV-III in cells cultured from semen of two patients with AIDS. Science 1984; 226:449-451.
  169. Wolff H, Anderson DJ. Immunohistologic characterization and quantitation of leukocyte subpopulations in human semen. Fertil Steril 1988; 49:497-504.
  170. Wolff H. The biologic significance of white blood cells in semen. Fertil Steril 1995; 63:1143-1157.
  171. Kung AW, Ho PC, Wang C. Seminal leucocyte subpopulations and sperm function in fertile and infertile Chinese men. Int J Androl 1993; 16:189-194.
  172. Tomlinson MJ, Barratt CL, Cooke ID. Prospective study of leukocytes and leukocyte subpopulations in semen suggests they are not a cause of male infertility. Fertil Steril 1993; 60:1069-1075.
  173. Denny TN, Scolpino A, Garcia A, Polyak A, Weiss SN, Skurnick JH, et al. Evaluation of T-lymphocyte subsets present in semen and peripheral blood of healthy donors: a report from the heterosexual transmission study. Cytometry 1995; 20:349-355.
  174. Quayle AJ, Coston WM, Trocha AK, Kalams SA, Mayer KH, Anderson DJ. Detection of HIV-1-specific CTLs in the semen of HIV-infected individuals. J Immunol 1998; 161:4406-4410.
  175. D'Alessio A, Riccioli A, Lauretti P, Padula F, Muciaccia B, De Cesaris P, et al. Testicular FasL is expressed by sperm cells. Proc Natl Acad Sci U S A 2001; 98:3316-3321.
  176. Riccioli A, Salvati L, D'Alessio A, Starace D, Giampietri C, De Cesaris P, et al. The Fas system in the seminiferous epithelium and its possible extra-testicular role. Andrologia 2003; 35: 64-70.
  177. Filippini A, Riccioli A, Padula F, Lauretti P, D'Alessio A, De Cesaris P, et al. Control and impairment of immune privilege in the testis and in semen. Hum Reprod Update 2001; 7: 444-449.
  178. Stites DP, Erickson RP. Suppressive effect of seminal plasma on lymphocyte activation. Nature 1975, 253:727-729.
  179. Mundle SD, Teni TR, Sheth NA. Inhibition of PHA-stimulated proliferation of peripheral blood mononuclear cells by human seminal plasma inhibin (HSPI). J Clin Lab Immunol 1992; 38:187-193.
  180. Miao D, Skibinski G, James K. The effects of human seminal plasma and PGE2 on mitogen induced proliferation and cytokine production of human splenic lymphocytes and peripheral blood mononuclear cells. J Reprod Immunol 1996; 30: 97-114.
  181. Clavert A, Gabriel-Robez O, Montagnon D. Physiological role of the seminal vesicle. Prog Reprod Biol Med 1985; 12:80-94.
  182. Quan CP, Roux C, Pillot J, Bouvet JP. Delineation between T and B suppressive molecules from human seminal plasma: II. Spermine is the major suppressor of T-lymphocytes in vitro. Am J Reprod Immunol 1990; 22:64-69.
  183. Quayle AJ, Kelly RW, Hargreave TB, James K. Immunosuppression by seminal prostaglandins. Clin Exp Immunol 1989; 75:387-391.
  184. Gentile M, Adrian T, Scheidler A, Ewald M, Dianzani F, Pauli G, Gelderblom HR. Determination of the size of HIV using adenovirus type 2 as an internal length marker. J Virol Methods 1994; 48:43-52.
  185. Campbell S, Rein A. In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain. J Virol 1999; 73:2270-2279.
  186. Mullen TE Jr, Kiessling RL, Kiessling AA. Tissue-specific populations of leukocytes in semen-producing organs of the normal, hemicastrated, and vasectomized mouse. AIDS Res Hum Retroviruses 2003; 19:235-243.